2.要約四半期連結財務諸表及び主な注記
(1)要約四半期連結財政状態計算書
| | (単位:千円) |
| 前連結会計年度 (2024年12月31日) | 当第1四半期連結会計期間 (2025年3月31日) |
資産 | | |
流動資産 | | |
現金及び現金同等物 | 1,454,908 | 1,264,124 |
売上債権 | 5,000 | 5,324 |
棚卸資産 | 10,073 | 9,966 |
その他の流動資産 | 61,312 | 62,864 |
流動資産合計 | 1,531,293 | 1,342,278 |
非流動資産 | | |
その他の非流動資産 | 10,614 | 8,819 |
非流動資産合計 | 10,614 | 8,819 |
資産合計 | 1,541,907 | 1,351,097 |
| | |
負債及び資本 | | |
負債 | | |
流動負債 | | |
買掛金 | 28,145 | 3,843 |
未払債務 | 52,287 | 67,802 |
未払報酬 | 53,591 | 31,009 |
リース負債 | 10,151 | 16,387 |
その他の流動負債 | 7,089 | 5,782 |
流動負債合計 | 151,263 | 124,823 |
非流動負債 | | |
リース負債 | 889 | 14,615 |
非流動負債合計 | 889 | 14,615 |
負債合計 | 152,152 | 139,438 |
資本 | | |
資本金 | 33,964 | 71,963 |
資本剰余金 | 27,867,241 | 27,910,792 |
利益剰余金 | △25,056,642 | △25,315,218 |
その他の資本の構成要素 | △1,454,808 | △1,455,878 |
親会社の所有者に帰属する持分合計 | 1,389,755 | 1,211,659 |
資本合計 | 1,389,755 | 1,211,659 |
負債及び資本合計 | 1,541,907 | 1,351,097 |
E3285445960窪田製薬ホールディングス株式会社Kubota Pharmaceutical Holdings Co., Ltd.四半期第3号参考様式 [IFRS](連結)IFRStrueCTE2025-01-012025-03-31Q12025-12-312024-01-012024-03-312024-12-311falsefalsefalse459602024-03-31jpigp_cor:RetainedEarningsIFRSMember459602024-03-31jpigp_cor:CapitalSurplusIFRSMember459602024-03-31jpigp_cor:ShareCapitalIFRSMember459602024-01-012024-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember459602024-01-012024-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember459602024-01-012024-03-31jpigp_cor:RetainedEarningsIFRSMember459602024-01-012024-03-31jpigp_cor:CapitalSurplusIFRSMember459602024-01-012024-03-31jpigp_cor:ShareCapitalIFRSMember459602023-12-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember459602023-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember459602023-12-31jpigp_cor:RetainedEarningsIFRSMember459602023-12-31jpigp_cor:CapitalSurplusIFRSMember459602023-12-31jpigp_cor:ShareCapitalIFRSMember459602025-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember459602025-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember459602025-03-31jpigp_cor:RetainedEarningsIFRSMember459602025-03-31jpigp_cor:CapitalSurplusIFRSMember459602025-03-31jpigp_cor:ShareCapitalIFRSMember459602025-01-012025-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember459602025-01-012025-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember459602025-01-012025-03-31jpigp_cor:RetainedEarningsIFRSMember459602025-01-012025-03-31jpigp_cor:CapitalSurplusIFRSMember459602025-01-012025-03-31jpigp_cor:ShareCapitalIFRSMember459602024-12-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember459602024-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember459602024-12-31jpigp_cor:RetainedEarningsIFRSMember459602024-12-31jpigp_cor:CapitalSurplusIFRSMember459602024-12-31jpigp_cor:ShareCapitalIFRSMember459602024-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember459602024-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember459602025-05-14459602025-03-31459602025-01-012025-03-31459602024-01-012024-03-31459602024-12-31459602023-12-31459602024-03-31iso4217:JPYxbrli:sharesiso4217:JPYxbrli:pure